FY2025 · ended Dec 31, 2025 · Revenue $27.47M, +195.7% YoY · Filed Mar 16, 2026
Cue Biopharma, Inc. (CUE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $27.5 million and a net loss of $26.6 million. Free cash flow was -$21.9 million. As of Jun 30, 2026 it held $17.4 million in cash and investments and $3.1 million in total debt.
Revenue (TTM)
$37.66M
+354.4% vs year-ago TTM
Net income (TTM)
$-164.11M
-321.9% vs year-ago TTM
Operating cash flow (TTM)
$-50.05M
-77.8% vs year-ago TTM
Free cash flow (TTM)
$-50.17M
-77.1% vs year-ago TTM
EPS (TTM)
$-1.71
-45.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
97.66M
+58.0% vs prior year
Net cash
$14.31M
as of Jun 30, 2026
Operating margin
-262.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CUE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Somerville, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1645460
- Former names
- Imagen Biopharma, Inc. (until Jun 19, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M |
| Operating income | -$26.6M | -$41.5M | -$52.1M | -$53.2M | -$43.7M |
| Net income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | -$44.2M |
| Diluted EPS | -$0.28 | -$0.72 | -$1.11 | -$1.49 | — |
| Operating cash flow | -$21.7M | -$36.3M | -$40.0M | -$41.8M | -$38.8M |
| Free cash flow | -$21.9M | -$36.4M | -$40.0M | -$42.0M | -$39.8M |
| Total assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M |
| Total liabilities | $15.8M | $14.7M | $24.4M | $25.6M | $17.9M |
| Stockholders' equity | $26.4M | $17.5M | $37.1M | $65.7M | $65.5M |
| Cash and investments | $54.2M | $22.5M | $48.5M | $76.3M | $64.4M |
| Total debt | $4.2M | $4.6M | $8.2M | $19.4M | $10.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 21, 2026 | Sep 20, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 3, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Other events
|
Jul 10, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 3, 2026 | Jun 1, 2026 |
All 552 Cue Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.